期刊文献+

中国年轻骨髓增殖性肿瘤患者的临床和基因突变特征

Clinical and genetic characteristics of young patients with myeloproliferative neoplasms
原文传递
导出
摘要 目的探究中国年轻骨髓增殖性肿瘤(MPN)患者的临床和基因突变特征。方法通过横断面研究,在全国范围内向MPN患者发放调查问卷,根据诊断时年龄分为年轻组(≤40岁)、中年组(41~60岁)和老年组(>60岁),在各疾病类型中比较三组的差异。结果共收集到1727份可供分析的问卷,其中年轻组453例(26.2%),包括原发性血小板增多症(ET)274例、真性红细胞增多症(PV)80例、骨髓纤维化(MF)99例(原发性MF 45例,PV后MF 20例,ET后MF 34例);男性178例(39.3%),中位年龄31(18~40)岁。与中年、老年MPN受访者相比,年轻MPN受访者中未婚、高学历、无合并症、无合并用药、较低危险度分层占比较高(P<0.001)。年轻MPN受访者中以头痛为首发症状患者占比较高(ET:P<0.001;PV:P=0.007;MF:P=0.001),脾大的比例在初诊(PV:P<0.001)和调研时(ET:P=0.052;PV:P=0.063)最高,而血栓事件的发生率在初诊(ET:P<0.001;PV:P=0.011)和调研时(ET:P<0.001;PV:P=0.003)均最低。年轻MPN受访者JAK2突变比例最低(ET:P<0.001;PV:P<0.001;MF:P=0.013),CALR突变比例最高(ET:P<0.001;MF:P=0.015),非驱动基因突变(ET:P=0.042;PV:P=0.043;MF:P=0.004)和高分子风险(HMR)突变(ET:P=0.024;PV:P=0.023;MF:P=0.001)的检出率均最低。结论与中、老年患者相比,年轻MPN患者有着特有的临床表现和基因突变特征。 Objectives To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms(MPN).Methods In this cross-sectional study,anonymous questionnaires were distributed to patients with MPN patients nationwide.The respondents were divided into 3 groups based on their age at diagnosis:young(≤40 years),middle-aged(41-60 years),and elderly(>60 years).We compared the clinical and genetic characteristics of three groups of MPN patients.Results 1727 assessable questionnaires were collected.There were 453(26.2%)young respondents with MPNs,including 274 with essential thrombocythemia(ET),80 with polycythemia vera(PV),and 99 with myelofibrosis.Among the young group,178(39.3%)were male,and the median age was 31(18-40)years.In comparison to middle-aged and elderly respondents,young respondents with MPN were more likely to present with a higher proportion of unmarried status(all P<0.001),a higher education level(all P<0.001),less comorbidity(ies),fewer medications(all P<0.001),and low-risk stratification(all P<0.001).Younger respondents experienced headache(ET,P<0.001;PV,P=0.007;MF,P=0.001)at diagnosis,had splenomegaly at diagnosis(PV,P<0.001),and survey(ET,P=0.052;PV,P=0.063).Younger respondents had fewer thrombotic events at diagnosis(ET,P<0.001;PV,P=0.011)and during the survey(ET,P<0.001;PV,P=0.003).JAK2 mutations were found in fewer young people(ET,P<0.001;PV,P<0.001;MF,P=0.013);however,CALR mutations were found in more young people(ET,P<0.001;MF,P=0.015).Furthermore,mutations in non-driver genes(ET,P=0.042;PV,P=0.043;MF,P=0.004)and high-molecular risk mutations(ET,P=0.024;PV,P=0.023;MF,P=0.001)were found in fewer young respondents.Conclusion Compared with middle-aged and elderly patients,young patients with MPN had unique clinical and genetic characteristics.
作者 张梦雨 宝梅 石红霞 刘晓力 许娜 段明辉 庄俊玲 杜新 秦玲 惠吴函 梁蓉 王梅芳 陈烨 李冬云 杨威 唐古生 张伟华 匡霞 苏伟 韩艳秋 陈丽梅 许霁虹 刘卓刚 黄健 赵春亭 佟红艳 胡建达 陈春燕 陈协群 肖志坚 江倩 Zhang Mengyu;Bao Mei;Shi Dayu;Shi Hongxia;Liu Xiaoli;Xu Na;Duan Minghui;Zhuang Junling;Du Xin;Qin Ling;Hui Wuhan;Liang Rong;Wang Meijfang;Chen Ye;Li Dongyun;Yang Wei;Tang Gusheng;Zhang Weihua;Kuang Xia;Su Wei;Han Yanqiu;Chen Limei;Xu Jihong;Liu Zhuogang;Huang Jian;Zhao Chunting;Tong Hongyan;Hu Jianda;Chen Chunyan;Chen Xiequn;Xiao Zhijian;JiangQian(Peking University People's Hospital,Bejing 100044,China;Nanfang Hospital,Southern Medical University,Guangzhou 510080,China;Peking Union Medical College Hospital,CAMS&PUMC,Beijing 100730,China;Department of Hematology,Shenzhen Second People's Hospital(First Affiliated Hospital of Shenzhen University),Shenzhen 518035,China;The First Afiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology,Zhenzhou 471003,China;Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Xi Jing Hospital,The Fourth Military Medical University,Xi'an 710032,China;Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China;Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Shengjing Hospital Affiliated to China Medical University,Shenyang l10020,China;Department of Hematology,Institute of Hematology,The First Affiliated Hospital of Naval Medical University,Changhai Hospital,Shanghai 200433,China;First Hospital of Shanxi Medical University,Taiyuan 300012,China;Kaifeng Central Hospital,Kaifeng 475000,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Department of Hematology,the First Hospital of Qiqihar,Qiqihar 161005,China;The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 322000,China;The Affiliated Hospital of Qingdao University,Qingdao 266003,China;The First Affiliated Hospital of College of Medicine,Zhejiang University,Hangzhou 310003,China;Fujian Medical University Union Hospital,Fuzhou 350001,China;Shandong University Qilu Hospital,Jinan 250012,China;Northwest University School of Medicine,Xi'an 710069,China;Institute of Hematology and Blood Diseases Hospital,CAMS&PUMC,National Clinical Research Center for Blood Diseases,The State Key Laboratory of Experimental Hematology,Tianjin 300020,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2023年第3期193-201,共9页 Chinese Journal of Hematology
基金 国家自然科学基金(81970140)。
关键词 骨髓增殖性肿瘤 临床表现 基因突变 NGS分析 Myeloproliferative neoplasms Clinical manifestations Genetic mutations Next-generation sequencing
  • 相关文献

参考文献4

二级参考文献50

  • 1Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical Concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi:10.1200/JCO. 2010.31.8436.
  • 2Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [J]. N Engl J Med, 2007, 356(5) :459-468. doi: 10.1056/NEJMoa065202.
  • 3Bench A J, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations [ J ]. Br J Haematol, 2013, 160(1):25-34. doi: 10.1111/bjh.12075.
  • 4Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification [J]. Am J Hematol, 2014, 89(2):199-202. doi: 10.1002/ajh.23617.
  • 5Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnos- tic criteria of polycythemia vera [J]. Leukemia, 2014, 28 (6): 1191-1195. doi: 10.1038/leu.2013.380.
  • 6Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post- polycythemia vera and post- essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment [J]. Leukemia, 2008, 22(2):437-438. doi:10.1038/sj. leu.2404914.
  • 7Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an intemational study[J]. Leukemia, 2013, 27(9):1874-1881. doi: 10.1038/1eu.2013.163.
  • 8Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera [J]. N Engl J Med, 2013, 368( 1 ):22-33. doi: 10.1056/NEJMoa1208500.
  • 9Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera [J]. N Engl J Med, 2004, 350(2):114-124. doi: 10.1056/NEJMoa035572.
  • 10Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis [J]. Expert Rev Hematol, 2013, 6 ( 1 ):49-58. doi:10.1586/ehm.12.69.

共引文献170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部